Who we are


Alopecia Areata: The shame and embarrassment of this disease devastates the lives of too many women and girls when treatments do not work. Since 2007 Bald Girls Do Lunch has connected with over 3,000 to restore self-confidence and conquer isolation. With requests for meet-ups in every state and beyond the USA, Bald Girls is answering the plea for women to find others for community and support. From intimate groups to style workshops to restoring her looks, BGDL puts women on the track to normalcy and living well with this disease. Learn more...



BGDL Facebook Page


  • Upcoming Events




Posts


Alopecia Areata Research Update from Mount Sinai

August 9th, 2016 by Chassin

Guttamn Staff
Dept of Dermatology Researchers, Icahn School of Medicine, Mount Sinai Health System

Here at Mount Sinai School of Medicine, it is an exciting time for treatment in alopecia areata. Currently we have three trials going on: an injectable, a topical and an oral. Read More

Read More


Lumigan is a hot topic – but not for AA, yet.

December 4th, 2008 by Chassin

 It was announced in a press release by Allergan Inc. on 12/3/08 that the drug Lumigan, currently approved to treat glaucoma, is close to FDA approval for cosmetic use as an eyelash growth enhancer for upper lashes – but don’t get excited if you have extensive loss due to AA. It had been discovered in clinical studies that a side effect in glaucoma patients was the growth of longer, darker and fuller lashes. The FDA posted a review of the drug on its Web site Wednesday ahead of a Friday review by an outside panel of medical experts. The advisory panel is being asked to vote on whether it thinks Latisse ( the proposed brand name) should be approved. The FDA usually follows its panels’ advice. If approved, the product would be the first FDA-approved product sold for eyelash enhancement.

Two pilot studies were done with alopecia areata volunteers at the  University of California San Francisco using Lumigan or Xalatan on patients with greater than 50 percent eyelash loss and concluded that it was not effective. No study has yet been done on AA patients with less than 50 percent loss. These pilot studies were a joint effort of the UCSF departments of dermatology and opthalmology with principal investigators Drs. Price and Stamper.

And as with all drugs, there will be risks and the potential for serious side effects in some people.

Click here for FDA briefing documents.